Ilmarinen Mutual Pension Insurance Co Grows Stock Holdings in Pfizer Inc. (NYSE:PFE)

Ilmarinen Mutual Pension Insurance Co grew its position in shares of Pfizer Inc. (NYSE:PFE) by 48.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 982,000 shares of the biopharmaceutical company’s stock after purchasing an additional 322,000 shares during the period. Ilmarinen Mutual Pension Insurance Co’s holdings in Pfizer were worth $26,052,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Nordea Investment Management AB boosted its stake in Pfizer by 36.1% in the fourth quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company’s stock worth $108,002,000 after buying an additional 1,080,822 shares in the last quarter. Parsons Capital Management Inc. RI boosted its stake in shares of Pfizer by 118.7% in the 4th quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company’s stock valued at $7,820,000 after purchasing an additional 159,984 shares in the last quarter. Copley Financial Group Inc. bought a new position in shares of Pfizer during the 3rd quarter valued at $577,000. Zacks Investment Management raised its position in Pfizer by 10.9% in the 3rd quarter. Zacks Investment Management now owns 2,389,138 shares of the biopharmaceutical company’s stock worth $69,142,000 after purchasing an additional 235,243 shares during the period. Finally, Geode Capital Management LLC lifted its stake in Pfizer by 1.6% in the third quarter. Geode Capital Management LLC now owns 117,666,245 shares of the biopharmaceutical company’s stock worth $3,392,342,000 after purchasing an additional 1,855,419 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now directly owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.06% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on PFE. Truist Financial decreased their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Finally, Bank of America reiterated a “neutral” rating and set a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, seven have given a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Price Performance

Shares of NYSE PFE opened at $22.99 on Friday. Pfizer Inc. has a 1 year low of $22.95 and a 1 year high of $31.54. The stock has a market capitalization of $130.39 billion, a P/E ratio of 16.31, a P/E/G ratio of 0.64 and a beta of 0.61. The company’s 50-day moving average is $25.87 and its 200 day moving average is $26.76. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the prior year, the company earned $0.10 EPS. The business’s revenue was up 24.7% compared to the same quarter last year. On average, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.